Crohn's Disease

Polygenic risk scores compiled using data from a multi-ethnic biobank helped improve predictions for inflammatory bowel disease, according to study results.

Healio Gastroenterology looks back at the Peer Tested content from online and print as it fared throughout the year and what made us stand out in 2020.

Over the last decade-plus, the introduction of several key therapies has shaped the management of inflammatory bowel disease.

In this exclusive video, Jessica Allegretti, MD, MPH, discussed the use of fecal microbiota transplantation to treat Clostridioides difficile infection in inflammatory bowel disease, IBD alone and to treat patients with J-pouches.

In this exclusive video, Miguel Regueiro, MD, from Cleveland Clinic, discusses the effort to hold the first virtual Advances in Inflammatory Bowel Diseases conference.

Stelara may be an effective therapeutic treatment in perianal refractory Crohn’s disease, according to results from the American Journal of Gastroenterology.

The Leona M. and Harry B. Helmsley Charitable Trust awarded nearly $4.7 million to fund three studies designed to explore dietary interventions for Crohn’s disease, according to a press release.

Patients with inflammatory bowel disease who reduced the frequency of Entyvio dosing showed high persistence and low rates of relapse, according to study results.

During the American College of Gastroenterology Annual Meeting, I had the honor of hosting the third Healio Disruptive Innovators Awards. Though this event looked different this year – as do so many of our traditions – we enjoyed naming our 2020 Healio Disruptive Innovators.

In this exclusive video, Jordan Axelrad, MD, MPH, from NYU Langone Health discusses his study from the American College of Gastroenterology Virtual Annual Scientific Meeting on the impact of baseline endoscopic and histologic activity on inflammatory bowel disease-related hospitalization.